List of Excipients in Branded Drug XADAGO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
MDD US Operations LLC a subsidiary of Supernus Pharmaceuticals Inc	XADAGO	safinamide mesylate	27505-110	CELLULOSE, MICROCRYSTALLINE
MDD US Operations LLC a subsidiary of Supernus Pharmaceuticals Inc	XADAGO	safinamide mesylate	27505-110	CROSPOVIDONE
MDD US Operations LLC a subsidiary of Supernus Pharmaceuticals Inc	XADAGO	safinamide mesylate	27505-110	FERRIC OXIDE RED
MDD US Operations LLC a subsidiary of Supernus Pharmaceuticals Inc	XADAGO	safinamide mesylate	27505-110	HYPROMELLOSE

Xadago Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Xadago, the brand name for safinamide tablets, is an oral adjunctive treatment for Parkinson's disease. Its current commercial formulation is a conventional film-coated immediate-release tablet containing safinamide mesylate in 50 mg and 100 mg strengths. The most credible excipient opportunities are generic cost reduction, lactose-free reformulation, improved swallowability, alternate-dose flexibility, and lifecycle products that support adherence.

Safinamide is a small molecule, so biosimilar competition is irrelevant. Competition will come from ANDA generics, authorized-generic arrangements, and 505(b)(2) products with differentiated dosage forms or excipient systems. Excipient changes alone will generally have limited commercial value unless they improve manufacturing economics, patient usability, tolerability, or regulatory differentiation.

What excipients are used in Xadago tablets?

Xadago is an immediate-release, film-coated tablet. The FDA-approved labeling identifies a conventional solid oral formulation with a tablet core and film-coating system.[1]

Formulation element	Xadago strategy	Commercial relevance
Active ingredient	Safinamide mesylate	Provides dose-equivalent safinamide
Dosage forms	50 mg and 100 mg film-coated tablets	Supports titration and maintenance dosing
Release profile	Immediate release	Limits formulation complexity but increases generic substitutability
Tablet core	Conventional filler, binder, disintegrant, glidant and lubricant system	Offers cost and process-optimization opportunities
Film coating	Conventional protective and appearance coating	Permits color, branding and swallowability differentiation
Administration	Oral tablets taken once daily with levodopa therapy	Creates adherence and convenience opportunities
Food considerations	Can be administered with or without food under the prescribing information	Reduces need for food-effect positioning as a commercial differentiator

The reference product uses standard pharmaceutical excipient technology rather than a modified-release, multiparticulate, osmotic or lipid-based platform. That structure lowers manufacturing barriers for generic manufacturers.

The precise inactive-ingredient composition, supplier grades and manufacturing process parameters remain important because excipient substitution can affect blend uniformity, tablet hardness, disintegration, dissolution, impurity formation and stability. A generic applicant does not need to copy every excipient, but it must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.[2]

Which excipient strategies have the highest commercial value for Xadago?

The strongest opportunities are tied to patient use and manufacturing economics rather than new pharmacology.

Lactose-free and gastrointestinal-tolerability formulations

A lactose-free tablet could address patients with lactose intolerance, excipient sensitivity or preferences for simplified labeling. Lactose is a common tablet diluent, but it is not essential to immediate-release safinamide manufacturing.

Potential replacements include:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Coprocessed cellulose-based excipients

Mannitol and microcrystalline cellulose are commercially attractive because they support direct compression and can improve patient acceptability. Mannitol can also provide a cleaner sensory profile if an orally disintegrating or chewable product is developed.

The commercial value is moderate for a standard generic. It becomes higher if the product is positioned for patients who experience swallowing difficulty or who seek lactose-free Parkinson's medicines.

Direct-compression and continuous-manufacturing platforms

Safinamide tablets appear suitable for conventional high-shear wet granulation or direct compression, depending on powder-flow and dose-uniformity characteristics. A direct-compression platform could reduce water exposure, drying time, equipment requirements and manufacturing cost.

Key formulation targets include:

• Adequate powder flow
• Low segregation risk
• Consistent low-dose uniformity
• Rapid disintegration
• Robust dissolution across pH conditions
• Sufficient tablet tensile strength
• Low friability during packaging and transport

A low-dose 50 mg tablet may present greater content-uniformity risk than the 100 mg strength because the active represents a smaller proportion of tablet mass. A carrier system with controlled particle size and strong blend homogeneity may be more important than the choice of any single excipient.

For a generic manufacturer, this strategy can improve gross margin. It is less likely to create durable market exclusivity because process advantages are often difficult to enforce against competitors unless protected by manufacturing patents or trade secrets.

Improved swallowability

Parkinson's disease patients may experience dysphagia, impaired dexterity and difficulty handling tablets. Film-coat optimization can reduce tablet friction, improve mouthfeel and support swallowing.

Commercially relevant approaches include:

• Low-friction film coatings
• Smaller tablet geometry
• Rounded tablet edges
• Lower tablet mass
• High-density formulations
• Easy-open blister packaging
• Tablets with stronger visual differentiation between strengths

The reference product's standard film-coated format leaves room for patient-centered design. A smaller or smoother tablet may have value even when the active ingredient and release profile remain unchanged.

Orally disintegrating tablets

An orally disintegrating tablet could address patients who have difficulty swallowing conventional tablets. Mannitol, crospovidone, croscarmellose sodium and low-substituted hydroxypropyl cellulose are common components in such systems.

The development risks are material:

• Safinamide taste masking
• Moisture sensitivity
• Mechanical fragility
• Packaging requirements
• Dose uniformity
• Dissolution equivalence
• Demonstration of bioequivalence

An ODT would likely require a 505(b)(2) application or another regulatory pathway depending on the formulation and proposed labeling. It would not automatically qualify as an ANDA substitutable for the reference tablet if the dosage form or labeling differs materially.

This is a higher-value but higher-risk opportunity than a conventional generic. The most attractive target is a product designed for Parkinson's patients with dysphagia rather than a nominally different tablet with no measurable usability benefit.

Sprinkle or dispersible formulations

A dispersible tablet or capsule product could be useful for patients unable to swallow intact tablets. The formulation would need to establish:

• Uniform dispersion
• Acceptable taste
• Stability after dispersion
• Compatibility with soft food or liquids
• Dose recovery from the administration vessel
• Appropriate labeling

This strategy may have a narrow but defensible market. It is more likely to support a differentiated 505(b)(2) product than a conventional ANDA.

What formulation patents could protect a Xadago lifecycle product?

Formulation patents could protect the dosage form, excipient ratio, manufacturing process, particle engineering, taste-masking system or dissolution profile. The most defensible claims would link the excipient system to a measurable technical result.

Potential claim categories include:

Patent category	Example technical focus	Relative strength
ODT composition	Safinamide with mannitol, superdisintegrant and taste-masking agent	Moderate if narrowly supported
Sprinkle formulation	Stable dispersed dose compatible with food or liquid	Moderate
Moisture-controlled tablet	Low water activity with improved stability	Moderate to strong if data are persuasive
Particle engineering	Controlled particle size or crystalline form	Stronger where it affects performance
Manufacturing process	Continuous blending or compression process	Strong as trade secret; variable as patent
Coating system	Low-friction or protective film coating	Usually narrow
Excipient ratio	Defined ranges producing dissolution or stability results	Vulnerable if routine optimization is apparent
Packaging-excipient combination	Desiccant, blister and moisture-control system	Often narrow but commercially useful

A patent directed only to replacing lactose with mannitol would face obviousness and enablement pressure if the substitution is routine. Stronger protection would require comparative data showing an unexpected result, such as improved stability, lower impurity growth, superior dissolution robustness or materially improved tablet handling.

A lifecycle patent should be filed before public launch and before disclosure of the formulation to customers or manufacturing partners. Patent protection should cover composition, process and use claims where the data support each category.

When does Xadago lose exclusivity and when can generics launch?

Xadago received FDA approval in March 2017 under NDA 207145.[1] Safinamide is a small-molecule drug, and the five-year new chemical entity exclusivity period therefore ran from approval until March 2022, subject to the statutory rules governing ANDA submissions and patent certifications.[2]

Milestone	Approximate date or status
FDA approval of Xadago	March 2017
Five-year NCE exclusivity	Expired in March 2022
Generic submission pathway	ANDA, subject to listed patents and certifications
Primary competition risk	Paragraph IV ANDA challenge and post-patent generic entry
Biosimilar pathway	Not applicable
Differentiated reformulation pathway	Potentially 505(b)(2), depending on product design
Commercial launch timing	Controlled by patent expiry, litigation, settlement terms and regulatory approval

Patent expiry is distinct from regulatory exclusivity. The end of NCE exclusivity did not necessarily permit immediate commercial generic launch if Orange Book-listed patents remained enforceable or if a Paragraph IV litigation stay applied.

The operative date for generic launch depends on:

1. The patents listed for Xadago in the current FDA Orange Book.
2. The expiration date and any patent-term adjustment or extension.
3. Whether an ANDA applicant certifies Paragraph III or Paragraph IV.
4. Whether the patent holder sues within the statutory period.
5. Whether a 30-month stay applies.
6. Whether the parties reach a settlement with an agreed entry date.
7. Whether the applicant obtains approval with a section viii carve-out for method-of-use claims.

The commercial assessment should therefore use the current Orange Book and FDA patent-listing records rather than relying solely on historical patent databases.[3]

What is the Orange Book and Paragraph IV status of Xadago?

Xadago's regulatory exposure is primarily an Orange Book and ANDA issue. The product is not exposed to biosimilar litigation because safinamide is not a biologic.

A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic. If the sponsor files a timely patent-infringement action, FDA approval can be subject to a statutory 30-month stay, unless the case is resolved earlier or the stay is altered by court action.[2]

A section viii statement may allow a generic applicant to omit a patented method of use from its labeling. That pathway is commercially relevant if Xadago patents cover a particular Parkinson's population, combination regimen or dosing instruction rather than the underlying composition.

For a generic manufacturer, the most attractive filing strategy is usually:

• Paragraph III certification for patents that cannot be bypassed;
• Paragraph IV certification for vulnerable composition or use patents;
• section viii carve-out for nonessential method-of-use claims;
• launch at patent expiry where litigation risk is high but settlement value is limited.

No specific current Paragraph IV challenger or settlement should be assumed without checking FDA litigation records, PACER and the latest Orange Book entry.

Which companies compete with Xadago?

Xadago competes in the adjunctive levodopa market, not only against safinamide generics.

Product	Active ingredient	Company or commercial group	Formulation relevance
Xadago	Safinamide	Supernus Pharmaceuticals in the U.S.; Newron-originated product	Immediate-release film-coated tablet
Azilect	Rasagiline	Teva and generic manufacturers	Conventional oral tablet
Selegiline products	Selegiline	Multiple manufacturers	Oral, orally disintegrating and transdermal options depending on product
Ongentys	Opicapone	Neurocrine/BIAL	Once-daily adjunctive COMT inhibitor
Comtan and generic entacapone	Entacapone	Multiple manufacturers	Conventional oral adjunct
Stalevo	Carbidopa, levodopa and entacapone	Novartis-originated product and generic competition	Combination tablet
Rytary	Carbidopa and levodopa	Amneal	Extended-release capsule

The main commercial substitutes are rasagiline, opicapone, entacapone and selegiline products. A safinamide generic with a lower acquisition cost may compete on formulary economics, while an improved formulation could compete on adherence and administration.

How strong is the Xadago patent estate?

The patent estate should be viewed as moderate for the original immediate-release product and potentially stronger for a genuinely differentiated reformulation.

Factors supporting strength

• Safinamide is a defined small-molecule active ingredient.
• Composition-of-matter protection, if still operative in a relevant jurisdiction, is generally stronger than formulation protection.
• Method-of-use claims may protect selected adjunctive treatment regimens.
• A technically distinct ODT, sprinkle product or stability-enhanced formulation could support new claims.

Factors limiting strength

• Conventional immediate-release tablets are relatively easy to formulate around.
• Standard excipient substitutions may be characterized as routine optimization.
• Generic applicants can use different excipient systems if they meet equivalence requirements.
• Method-of-use claims may be carved out of generic labeling.
• Commercial entry may occur through authorized-generic or settlement arrangements before all listed patents expire.

Patent strength should be scored claim by claim. A broad active-ingredient claim has different competitive value from a narrow tablet-composition claim. Public patent-family data, terminal disclaimers, patent-term adjustments and Orange Book listings should be reconciled before assigning a final loss-of-exclusivity date.

What regulatory pathways apply to Xadago excipient products?

ANDA pathway

An ANDA is the principal route for a conventional generic tablet that has the same active ingredient, strength, dosage form, route and labeling framework as Xadago. The applicant can use different excipients, subject to safety, quality and bioequivalence requirements.[2]

This is the lowest-cost route for a standard 50 mg or 100 mg immediate-release tablet. It offers limited differentiation and exposes the product to price erosion.

505(b)(2) pathway

A 505(b)(2) application may be appropriate for:

• An orally disintegrating tablet
• A dispersible or sprinkle product
• A modified administration method
• A materially different excipient system
• A new strength or formulation requiring reliance on some reference-product data

The product may qualify for three years of clinical-investigation exclusivity if approval relies on new clinical studies essential to approval. That protection does not block an ANDA for the original formulation, but it can delay approval of a competing product that relies on the same change.

New drug application pathway

A fully independent NDA would be commercially excessive for an excipient-only product unless the development includes substantial clinical differentiation, such as a new indication, delivery system or clinically meaningful tolerability benefit.

What manufacturing and intellectual-property barriers affect commercialization?

The technical barriers are manageable for a conventional generic but increase sharply for patient-centered delivery systems.

Key barriers include:

• Low-dose blend uniformity for the 50 mg strength
• Safinamide impurity control
• Moisture and photostability management
• Tablet hardness versus rapid disintegration
• Taste masking for ODT or dispersible products
• Packaging compatibility
• Demonstration of dissolution similarity
• Scale-up from laboratory compression to commercial production
• Supplier qualification for functional excipient grades
• Patent clearance for solid forms, formulations and methods of use

Excipient suppliers may create indirect competitive advantages through proprietary grades, technical support and validated processing windows. These advantages are usually commercial rather than exclusionary. A drug manufacturer that qualifies two suppliers for critical excipients can reduce supply risk, while a single-source strategy may improve consistency but increase vulnerability to shortages and price changes.

What revenue exposure and commercial opportunities exist?

The revenue risk is greatest for a conventional immediate-release generic because the product has limited formulation complexity and several therapeutic alternatives. Pricing pressure can emerge rapidly after multiple ANDA approvals.

The commercial opportunity is stronger in four areas:

1. A low-cost generic with reliable supply and broad payer access.
2. A lactose-free or smaller tablet aimed at tolerability and swallowing concerns.
3. An ODT or dispersible formulation for Parkinson's patients with dysphagia.
4. A combination or adherence-oriented product that reduces daily administration burden.

A reformulation should not be justified by excipient novelty alone. The commercial case should quantify:

• Expected treated population
• Share of patients with swallowing limitations
• Payer willingness to reimburse a premium
• Incremental manufacturing cost
• Likely generic substitution
• Patent term remaining at launch
• Incremental exclusivity available under 505(b)(2)
• Prescriber adoption and pharmacy substitution rules

The most defensible investment thesis is a targeted lifecycle product with a clear administration benefit, supported by composition and process patents and launched before the reference product's remaining commercial protection expires.

Key Takeaways

• Xadago is a conventional immediate-release safinamide tablet in 50 mg and 100 mg strengths.
• Standard excipient substitution supports generic cost reduction but rarely creates strong exclusivity.
• Lactose-free, smaller, low-friction, ODT and dispersible formats offer the clearest formulation opportunities.
• Safinamide is a small molecule, so biosimilar risk does not apply.
• The five-year NCE exclusivity period ended in March 2022; remaining launch barriers depend on Orange Book patents, litigation and settlements.
• A conventional generic is likely to face rapid price competition.
• A differentiated 505(b)(2) product could create more durable value if it solves dysphagia, administration or adherence problems.
• Strong formulation patents should claim measurable performance results, not routine excipient replacement alone.
• Current Orange Book listings and litigation records control the final generic-entry analysis.

FAQs

Can a lactose-free Xadago generic obtain FDA approval?

Yes. An ANDA applicant may use a different diluent or excipient system if the product meets applicable quality, safety, pharmaceutical-equivalence and bioequivalence requirements.

Could an Xadago orally disintegrating tablet receive new exclusivity?

Potentially. A materially different formulation approved through a 505(b)(2) application may qualify for three years of exclusivity if new clinical investigations were essential to approval.

Is safinamide suitable for a fixed-dose combination product?

Potentially, but compatibility, dose flexibility, labeling, patent clearance and clinical justification would determine feasibility. A fixed-dose combination would likely require a more complex regulatory strategy than a standard generic.

What excipient is most attractive for an Xadago ODT?

Mannitol is a leading candidate because it supports mouthfeel and direct compression, but the final system would also require a superdisintegrant, binder or co-binder, lubricant, taste-masking approach and moisture-control packaging.

Can a generic omit a patented Xadago indication?

Possibly. A section viii labeling carve-out may permit omission of a patented method of use if the remaining labeling does not encourage infringement and FDA accepts the proposed labeling.

References

1. U.S. Food and Drug Administration. (2017). Xadago (safinamide) tablets, prescribing information. NDA 207145.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th ed. Orange Book.

3. U.S. Food and Drug Administration. (2024). Approved drug product and patent information resources. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.